Clinical Trial Update: Study of MLN8237 in Combination With Irinotecan and Temozolomide [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating MLN8237 in combination with irinotecan and temozolomide for neuroblastoma has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Irinotecan (Irinotecan)
• MLN8237 (alisertib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-31